William Blair Predicts Increased Earnings for Inari Medical

Inari Medical, Inc. (NASDAQ:NARI) – Research analysts at William Blair upped their FY2025 EPS estimates for shares of Inari Medical in a research report issued on Thursday, October 31st. William Blair analyst M. Kaczor now expects that the company will post earnings per share of $0.18 for the year, up from their previous estimate of $0.13. William Blair has a “Outperform” rating on the stock. The consensus estimate for Inari Medical’s current full-year earnings is ($0.74) per share.

NARI has been the subject of several other research reports. Piper Sandler increased their target price on shares of Inari Medical from $50.00 to $52.00 and gave the company a “neutral” rating in a report on Tuesday, October 29th. Wells Fargo & Company cut their price objective on Inari Medical from $84.00 to $65.00 and set an “overweight” rating on the stock in a research report on Wednesday, July 31st. Deutsche Bank Aktiengesellschaft assumed coverage on Inari Medical in a research report on Friday, August 9th. They set a “buy” rating and a $68.00 target price for the company. Robert W. Baird boosted their price target on shares of Inari Medical from $66.00 to $67.00 and gave the stock an “outperform” rating in a report on Tuesday, October 29th. Finally, Stifel Nicolaus initiated coverage on shares of Inari Medical in a research report on Tuesday, September 17th. They set a “hold” rating and a $50.00 price target for the company. Six investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $58.89.

Inari Medical Stock Up 2.3 %

NARI stock opened at $50.05 on Monday. The firm has a market capitalization of $2.93 billion, a PE ratio of -37.07 and a beta of 0.96. Inari Medical has a twelve month low of $36.73 and a twelve month high of $67.13. The stock’s 50 day moving average is $43.91 and its 200-day moving average is $46.31.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Point72 Asset Management L.P. boosted its stake in Inari Medical by 113.3% during the second quarter. Point72 Asset Management L.P. now owns 1,481,283 shares of the company’s stock valued at $71,324,000 after buying an additional 786,691 shares during the period. Armistice Capital LLC raised its holdings in shares of Inari Medical by 353.1% in the 2nd quarter. Armistice Capital LLC now owns 1,009,252 shares of the company’s stock valued at $48,595,000 after acquiring an additional 786,501 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Inari Medical by 11.1% during the 1st quarter. Vanguard Group Inc. now owns 5,599,854 shares of the company’s stock valued at $268,681,000 after acquiring an additional 561,562 shares during the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of Inari Medical by 1,219.9% during the second quarter. The Manufacturers Life Insurance Company now owns 394,901 shares of the company’s stock worth $19,014,000 after purchasing an additional 364,983 shares in the last quarter. Finally, First Light Asset Management LLC grew its holdings in shares of Inari Medical by 120.8% during the second quarter. First Light Asset Management LLC now owns 472,384 shares of the company’s stock worth $22,745,000 after purchasing an additional 258,444 shares in the last quarter. 90.98% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Inari Medical news, Director William Hoffman sold 40,000 shares of the business’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $45.83, for a total transaction of $1,833,200.00. Following the sale, the director now owns 643,296 shares of the company’s stock, valued at $29,482,255.68. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other news, CFO Mitch C. Hill sold 3,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $45.13, for a total value of $135,390.00. Following the completion of the transaction, the chief financial officer now directly owns 179,600 shares in the company, valued at approximately $8,105,348. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director William Hoffman sold 40,000 shares of the company’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $45.83, for a total transaction of $1,833,200.00. Following the sale, the director now directly owns 643,296 shares in the company, valued at $29,482,255.68. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 131,000 shares of company stock valued at $6,161,340. Company insiders own 10.60% of the company’s stock.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.